The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors

Journal of Interventional Cardiology

Volumn 15, Issue 1, 2002, Pages 45-60

  Jennings, Lisa K ^a   Jacoski, Mary V ^a   White, Melanie McCabe ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; PRIORITY JOURNAL; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0036122627     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2002.tb01034.x     Document Type: Review

References (68)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Pathogenesis of acute ischemic coronary syndromes
3. The interaction of von Willebrand factor and the platelet glycoprotein Ib-IX complex
4. Platelet activation by fibrinolytic agents: A potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis
5. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex
6. Calcium regulation of the platelet membrane glycoprotein IIb/IIIa complex
7. Calcium cation regulation of glycoprotein IIb/IIIa complex formation in platelet plasma membranes
8. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-III complex
9. ++dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis
10. The platelet membrane glycoprotein IIb/IIIa complex
11. Clinical pharmacology of eptifibatide
12. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
13. Cellular adhesion: GPIIb/IIIa as a prototype adhesion receptor
14. Role of fibrinogen a and g chain sites in platelet aggregation
15. Platelet receptor recognition site on human fibrinogen: Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the g-chain
16. Pharmacology and clinical development of abciximab (c7E3 Fab, ReoPro): A monoclonal antibody inhibitor of GPIIb/IIIa and a (V)b(3)
17. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors
18. 7E3 Monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1
19. Role of platelets in restenosis after percutaneous coronary revascularization
20. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)
21. Abciximab (c7E3 Fab): A review of its pharmacology and therapeutic potential in ischaemic heart disease
22. A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors
23. Drug-induced thrombocytopenia: Is it a serious concern for glycoprotein IIb/IIIa receptor inhibitors?
24. Development of eptifibatide
25. Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb/IIIa
26. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIA receptor
27. Bleeding time: A guide to its diagnostic and clinical utility
28. Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody
29. Pharmacology of the intravenous platelet receptor glycoprotein IIb/IIIa antagonists
30. The thrombin receptor extracellular domain contains sites crucial for peptide ligand-inducedactivation
31. Platelet interaction with collagen fibrils in flowing blood, I: Reaction of human platelets with a-chymotrypsin-digested subendothelium
32. Formation and regulation of platelet and fibrin hemostatic plug
33. Randomized, double-blind, placebo-controlled, dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty
34. Platelet aggregation inhibition with single and double bolus regimens of eptifibatide (Integrilin)
35. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
36. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
37. Platelet glycoprotein IIb/IIIa receptor blockade with high-dose INTEGRILIN™ in coronary intervention: Results of the PRIDE study
38. Differential effects of citrate versus PPACK anticoagulants: Implications for comparing glycoprotein IIb/IIIa inhibitors
39. Effect of anticoagulation and platelet agonist concentration on the inhibitory activities of GPIIb/IIIa antagonists
40. Extracellular-free Ca++ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma
41. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis
42. Effect of Ca2+ on GPIIb/IIIa interactions with integrilin: Enhanced GPIIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
43. Eptifibatide pharmacokinetic-pharmacodynamic relationship in coronary angioplasty patients: Results of the PRIDE study
44. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
45. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo-controlled trial
46. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist in healthy men
47. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade
48. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention: Rationale and design of the GOLD study
49. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
50. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention
51. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors
52. Quantitative detection of platelet GPIIb/IIIa receptor antagonist activity using a flow cytometric method
53. Quantifying GPIIb/IIIa receptor binding using two monoclonal antibodies: Discriminating abciximab and small molecular weight antagonists
54. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty
55. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors
56. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation
57. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina
58. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
59. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: Prospective analysis from the PURSUIT trial
60. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
61. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
62. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists
63. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: The GUSTO IV-ACS Trial
64. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
65. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction